Focus: Soligenix is a public biotech company focused on lipoprotein delivery and small-molecule therapeutics across oncology, gastroenterology, and immunology. The company is pre-revenue with a highly specialized pipeline centered on rare and orphan indications.
Profile data last refreshed Yesterday · AI intelligence enriched 3w ago
No open roles listed right now. Follow Soligenix to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Soligenix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Soligenix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Soligenix Seeks Funding for Bundibugyo Ebola Vaccine - AllSci
Soligenix Seeks Funding for Bundibugyo Ebola Vaccine AllSci
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine - BioSpace
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine BioSpace
SNGX - Finviz
SNGX Finviz
After halted skin-lymphoma trial, Soligenix weighs M&A with $6M cash - Stock Titan
After halted skin-lymphoma trial, Soligenix weighs M&A with $6M cash Stock Titan
Skin lymphoma drug study stops early after futility review - Stock Titan
Skin lymphoma drug study stops early after futility review Stock Titan
Soligenix Emphasizes Patient-Centric Reformulation Strategy in Drug Development - citybuzz -
Soligenix Emphasizes Patient-Centric Reformulation Strategy in Drug Development citybuzz -
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Clinical trial failure in April 2026 followed by M&A exploration in May 2026 indicates elevated restructuring risk over next 6–12 months.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo